Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACE | P12821 | 2/20 | 0.60 |
| ▸ | CYP19A1 | P11511 | 6/20 | 0.56 |
| ▸ | MMP3 | P08254 | 1/20 | 0.48 |
| ▸ | MMP8 | P22894 | 1/20 | 0.48 |
| ▸ | DRD5 | P21918 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29929342 | 1.00 | ACE (0.60) | ACECYP19A1MMP3MMP8DRD5 | |
| SCHEMBL9038284 | 0.83 | ACE (0.64) | ACECYP19A1MMP3MMP8 | |
| SCHEMBL6761709 | 0.83 | ACE (0.64) | ACECYP19A1MMP3MMP8 | |
| SCHEMBL9036399 | 0.83 | ACE (0.64) | ACECYP19A1MMP3MMP8 | |
| SCHEMBL30471119 | 0.79 | ACE (0.72) | ACECYP19A1MMP3MMP8DRD5 | |
| SCHEMBL677552 | 0.79 | ACE (0.67) | ACECYP19A1MMP3MMP8DRD5 | |
| SCHEMBL8243497 | 0.79 | ACE (0.67) | ACECYP19A1MMP3MMP8DRD5 | |
| SCHEMBL5880416 | 0.79 | ACE (0.67) | ACECYP19A1MMP3MMP8DRD5 | |
| SCHEMBL29666098 | 0.79 | ACE (0.67) | ACECYP19A1MMP3MMP8DRD5 | |
| SCHEMBL1137272 | 0.78 | FABP5 (0.46) | ACE |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 26 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9133104-B2 | Enzyme inhibitors | CHROMA THERAPEUTICS LTD. (GB) | 2015-09-15 | — | — | US | disclosed |
| US-20140163042-A1 | ENZYME INHIBITORS | CHROMA THERAPEUTICS LTD. (GB) | 2014-06-12 | — | — | US | disclosed |
| US-20130116318-A1 | Enzyme Inhibitors | CHROMA THERAPEUTICS LTD. (GB) | 2013-05-09 | — | — | US | disclosed |
| US-8410028-B2 | Methods for synthesis of encoded libraries | GLAXOSMITHKLINE LLC (US) | 2013-04-02 | — | — | US | disclosed |
| US-8410028-B2 | Methods for synthesis of encoded libraries | GLAXOSMITHKLINE LLC (US) | 2013-04-02 | — | — | US | disclosed |
| US-20120245040-A1 | METHODS FOR SYNTHESIS OF ENCODED LIBRARIES | GLAXOSMITHKLINE (US) | 2012-09-27 | — | — | US | disclosed |
| US-20120245040-A1 | METHODS FOR SYNTHESIS OF ENCODED LIBRARIES | GLAXOSMITHKLINE (US) | 2012-09-27 | — | — | US | disclosed |
| US-20120071329-A1 | METHODS FOR IDENTIFYING COMPOUNDS OF INTEREST USING ENCODED LIBRARIES | GLAXOSMITHKLINE LLC (US) | 2012-03-22 | — | — | US | disclosed |
| US-20120071329-A1 | METHODS FOR IDENTIFYING COMPOUNDS OF INTEREST USING ENCODED LIBRARIES | GLAXOSMITHKLINE LLC (US) | 2012-03-22 | — | — | US | disclosed |
| US-20110251089-A1 | METHODS FOR SYNTHESIS OF ENCODED LIBRARIES | GLAXOSMITHKLINE (US) | 2011-10-13 | — | — | US | disclosed |
| US-20110136697-A1 | METHODS FOR SYNTHESIS OF ENCODED LIBRARIES | PRAECIS PHARMACEUTICALS INCORPORATED (US) | 2011-06-09 | — | — | US | disclosed |
| US-7939666-B2 | Enzyme inhibitors | CHROMA THERAPEUTICS LTD. (GB) | 2011-05-10 | — | — | US | disclosed |
| US-7935658-B2 | Methods for synthesis of encoded libraries | PRAECIS PHARMACEUTICALS, INC. (US) | 2011-05-03 | — | — | US | disclosed |
| US-7935658-B2 | Methods for synthesis of encoded libraries | PRAECIS PHARMACEUTICALS, INC. (US) | 2011-05-03 | — | — | US | disclosed |
| EP-2301939-A1 | Enzyme inhibitors | Chroma Therapeutics Limited (GB) | 2011-03-30 | — | — | EP | disclosed |
| US-20090291978-A1 | Enzyme Inhibitors | CHROMA THERAPEUTICS LTD. (GB) | 2009-11-26 | — | — | US | disclosed |
| US-20090062147-A1 | Methods for synthesis of encoded libraries | PRAECIS PHARMACEUTICALS INCORPORATED (US) | 2009-03-05 | — | — | US | disclosed |
| US-20090062147-A1 | Methods for synthesis of encoded libraries | PRAECIS PHARMACEUTICALS INCORPORATED (US) | 2009-03-05 | — | — | US | disclosed |
| US-20070042401-A1 | Methods for synthesis of encoded libraries | PRAECIS PHARMACEUTICALS, INC. (US) | 2007-02-22 | — | — | US | disclosed |
| US-20070042401-A1 | Methods for synthesis of encoded libraries | PRAECIS PHARMACEUTICALS, INC. (US) | 2007-02-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130116318-A1 | Enzyme Inhibitors | HDAC1, HDAC11, HDAC7 | ACE 722/4885CYP19A1 533/4885MMP3 170/4885 |
| US-20120245040-A1 | METHODS FOR SYNTHESIS OF ENCODED LIBRARIES | RNGTT, DTYMK, DUT | ACE 421/4885CYP19A1 3388/4885MMP3 2314/4885 |
| US-20110251089-A1 | METHODS FOR SYNTHESIS OF ENCODED LIBRARIES | RNGTT, DTYMK, DUT | ACE 421/4885CYP19A1 3388/4885MMP3 2314/4885 |
| US-20140163042-A1 | ENZYME INHIBITORS | HAT1, NR2E1, HDAC3 | ACE 1098/4885CYP19A1 95/4885MMP3 395/4885 |
| US-20090291978-A1 | Enzyme Inhibitors | HAT1, NR2E1, NR2C2 | ACE 1130/4885CYP19A1 152/4885MMP3 698/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.